Biofrontera Inc.: A Compelling Investment in Dermatology
September 9, 2025
Pioneering Photodynamic Therapy for a Healthier Future
Biofrontera Inc. is a leader in Photodynamic Therapy (PDT), an in-office, non-invasive treatment for pre-cancerous lesions. Our FDA-approved combination product including AMELUZ® (aminolevulinic acid hydrochloride) topical gel, 10% and RhodoLED® lamp portfolio provide a superior, patient-friendly therapy for actinic keratosis (AK), a market impacting 58 million Americans. This dynamic product combination offers excellent clearance rates, providing dermatologists with a highly effective, patient-friendly therapy that seamlessly integrates into their workflows. Biofrontera has an experienced “Buy and Bill” salesforce that empowers clinics nationwide, continually expanding the company’s commercial footprint, providing PDT to more patients.
About Us
Why Biofrontera?
- Market Leadership: One of the proven leaders in U.S. PDT, but the only company with a growing clinical presence advancing PDT.
- Compelling Revenue Growth: Revenues about doubling from $18.8M (2020) to $37.3M (2024), with 2025 revenue growth accelerating.
- Improved Economics: A new agreement dramatically reduces royalties (from up to 35% to as little as 12%), significantly improving margins and cash flow.
- Breakthrough Financing: Recently secured up to $11 million in new funding, providing a clear runway to cash flow breakeven.
Company Highlights:
- Long-Term Patient Exclusivity: A new patent extends protection for AMELUZ® through December 2043 provides long-term product exclusivity.
- Robust Pipeline: Ongoing clinical trials for new high-value indications, including superficial basal cell carcinoma (BCC) and acne vulgaris, which represent billions in potential revenue based on affected patient populations.
- Dynamic Leadership: New Chief Commercial Officer George Jones, with over 25 years of commercial pharma experience, poised to accelerate nationwide adoption.